全文获取类型
收费全文 | 3448篇 |
免费 | 257篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 67篇 |
妇产科学 | 77篇 |
基础医学 | 402篇 |
口腔科学 | 81篇 |
临床医学 | 397篇 |
内科学 | 642篇 |
皮肤病学 | 61篇 |
神经病学 | 277篇 |
特种医学 | 90篇 |
外科学 | 408篇 |
综合类 | 50篇 |
一般理论 | 13篇 |
预防医学 | 460篇 |
眼科学 | 48篇 |
药学 | 344篇 |
中国医学 | 10篇 |
肿瘤学 | 245篇 |
出版年
2023年 | 22篇 |
2022年 | 16篇 |
2021年 | 82篇 |
2020年 | 79篇 |
2019年 | 103篇 |
2018年 | 105篇 |
2017年 | 89篇 |
2016年 | 113篇 |
2015年 | 94篇 |
2014年 | 126篇 |
2013年 | 209篇 |
2012年 | 264篇 |
2011年 | 326篇 |
2010年 | 173篇 |
2009年 | 154篇 |
2008年 | 252篇 |
2007年 | 264篇 |
2006年 | 246篇 |
2005年 | 227篇 |
2004年 | 178篇 |
2003年 | 181篇 |
2002年 | 171篇 |
2001年 | 39篇 |
2000年 | 19篇 |
1999年 | 18篇 |
1998年 | 23篇 |
1997年 | 12篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1970年 | 2篇 |
1968年 | 2篇 |
1967年 | 3篇 |
1966年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有3713条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Keren Cohen‐Hagai Andy Kotliroff Ilan Rozenberg Zeev Korzets Tali Zitman‐Gal Sydney Benchetrit 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2019,23(1):38-43
Infection is one of the leading causes of mortality in dialysis patients, second only to cardiovascular disease. This retrospective study assessed the efficacy and clinical outcomes of influenza vaccination among hemodialysis (HD) patients. In the 2014–2015 season, 104 of 164 (63.6%) HD patients were vaccinated for influenza by the outpatient community health system facilities. Significantly more patients, 159 of 170 (93.8%), were vaccinated in 2015–2016 by the hospital dialysis unit staff during an inpatient HD session (P <0.001). A trend toward fewer complications from influenza infection was observed in vaccinated patients. Among HD patients with diabetes (who comprised 56% of the study population), the incidence of influenza was 17% among nonvaccinated patients vs. 6.3% among those who were vaccinated (P =0.026). The inpatient vaccination policy resulted in a greater rate of vaccination. HD patients with diabetes benefit from influenza vaccination, with a significantly lower incidence of influenza infection. 相似文献
6.
7.
Prahlad V. Raninga Andy C. Lee Debottam Sinha Yu-Yin Shih Deepak Mittal Ashwini Makhale Amanda L. Bain Devathri Nanayakarra Kathryn F. Tonissen Murugan Kalimutho Kum Kum Khanna 《International journal of cancer. Journal international du cancer》2020,146(1):123-136
Triple-negative breast cancer (TNBCs) is a very aggressive and lethal form of breast cancer with no effective targeted therapy. Neoadjuvant chemotherapies and radiotherapy remains a mainstay of treatment with only 25–30% of TNBC patients responding. Thus, there is an unmet clinical need to develop novel therapeutic strategies for TNBCs. TNBC cells have increased intracellular oxidative stress and suppressed glutathione, a major antioxidant system, but still, are protected against higher oxidative stress. We screened a panel of antioxidant genes using the TCGA and METABRIC databases and found that expression of the thioredoxin pathway genes is significantly upregulated in TNBC patients compared to non-TNBC patients and is correlated with adverse survival outcomes. Treatment with auranofin (AF), an FDA-approved thioredoxin reductase inhibitor caused specific cell death and impaired the growth of TNBC cells grown as spheroids. Furthermore, AF treatment exerted a significant in vivo antitumor activity in multiple TNBC models including the syngeneic 4T1.2 model, MDA-MB-231 xenograft and patient-derived tumor xenograft by inhibiting thioredoxin redox activity. We, for the first time, showed that AF increased CD8+Ve T-cell tumor infiltration in vivo and upregulated immune checkpoint PD-L1 expression in an ERK1/2-MYC-dependent manner. Moreover, combination of AF with anti-PD-L1 antibody synergistically impaired the growth of 4T1.2 primary tumors. Our data provide a novel therapeutic strategy using AF in combination with anti-PD-L1 antibody that warrants further clinical investigation for TNBC patients. 相似文献
8.
Buijs Sheila B. Stuart Sanne K. Oosterheert Jan Jelrik Karhof Steffi Hoepelman Andy I. M. Renders Nicole H. M. van Petersen André S. Bleeker-Rovers Chantal P. Wever Peter C. Koning Olivier H. J. 《European journal of clinical microbiology & infectious diseases》2021,40(7):1569-1572
We evaluated the long-term serological follow-up of patients with vascular risk factors for chronic Q fever that were previously Coxiella burnetii seropositive. C. burnetii phase I IgG titers were reevaluated in patients that gave informed consent or retrospectively collected in patients already deceased or lost to follow-up. Of 107 patients, 25 (23.4%) became seronegative, 77 (72.0%) retained a profile of past resolved Q fever infection, and five (4.7%) developed chronic Q fever. We urge clinicians to stay vigilant for chronic Q fever beyond two years after primary infection and perform serological testing based on clinical presentation.
相似文献9.
10.
Daniel R. Brown Ashley R. Warner Sanjoy K. Deb Lewis A. Gough S. Andy Sparks Lars R. McNaughton 《Journal of Science and Medicine in Sport》2021,24(1):92-97
ObjectivesThis study aimed to investigate whether supplementation with 12 mg?day?1 astaxanthin for 7 days can improve exercise performance and metabolism during a 40 km cycling time trial.DesignA randomised, double-blind, crossover design was employed.MethodsTwelve recreationally trained male cyclists (VO2peak: 56.5 ± 5.5 mL?kg?1?min?1, Wmax: 346.8 ± 38.4 W) were recruited. Prior to each experimental trial, participants were supplemented with either 12 mg?day?1 astaxanthin or an appearance-matched placebo for 7 days (separated by 14 days of washout). On day 7 of supplementation, participants completed a 40 km cycling time trial on a cycle ergometer, with indices of exercise metabolism measured throughout.ResultsTime to complete the 40 km cycling time trial was improved by 1.2 ± 1.7% following astaxanthin supplementation, from 70.76 ± 3.93 min in the placebo condition to 69.90 ± 3.78 min in the astaxanthin condition (mean improvement = 51 ± 71 s, p = 0.029, g = 0.21). Whole-body fat oxidation rates were also greater (+0.09 ± 0.13 g?min?1, p = 0.044, g = 0.52), and the respiratory exchange ratio lower (?0.03 ± 0.04, p = 0.024, g = 0.60) between 39–40 km in the astaxanthin condition.ConclusionsSupplementation with 12 mg?day?1 astaxanthin for 7 days provided an ergogenic benefit to 40 km cycling time trial performance in recreationally trained male cyclists and enhanced whole-body fat oxidation rates in the final stages of this endurance-type performance event. 相似文献